Insulet Co. (NASDAQ:PODD) Shares Bought by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC boosted its holdings in Insulet Co. (NASDAQ:PODD) by 13.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,765 shares of the medical instruments supplier’s stock after buying an additional 8,713 shares during the period. Segall Bryant & Hamill LLC owned 0.10% of Insulet worth $18,736,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Empowered Funds LLC acquired a new stake in Insulet during the third quarter worth about $220,000. Intech Investment Management LLC acquired a new stake in Insulet during the 3rd quarter worth approximately $224,000. Cerity Partners LLC raised its holdings in Insulet by 78.5% in the third quarter. Cerity Partners LLC now owns 10,193 shares of the medical instruments supplier’s stock valued at $2,372,000 after buying an additional 4,484 shares during the period. Algert Global LLC lifted its position in Insulet by 393.8% during the third quarter. Algert Global LLC now owns 11,131 shares of the medical instruments supplier’s stock valued at $2,591,000 after buying an additional 8,877 shares in the last quarter. Finally, Swedbank AB grew its stake in Insulet by 3.2% during the third quarter. Swedbank AB now owns 21,232 shares of the medical instruments supplier’s stock worth $4,942,000 after buying an additional 655 shares during the period.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.47% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. StockNews.com lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Wells Fargo & Company upped their target price on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus raised their target price on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday, February 21st. Canaccord Genuity Group upped their price target on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Finally, Citigroup lifted their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Trading Down 0.5 %

Shares of NASDAQ PODD opened at $272.71 on Wednesday. The company has a market cap of $19.15 billion, a price-to-earnings ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The stock’s 50 day simple moving average is $272.27 and its 200 day simple moving average is $258.19. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Equities research analysts expect that Insulet Co. will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.